

Giuseppe Procopio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3591872/giuseppe-procopio-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211
papers

8,145
citations

35
h-index

87
g-index

230
ext. papers

10,192
ext. citations

4.7
avg, IF

5.34
L-index

#	Paper	IF	Citations
211	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.. <i>ESMO Open</i> , 2022 , 7, 100431	6	
210	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727	3.6	0
209	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021 , 107, 542-549	1.7	1
208	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7	3.5	2
207	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls. <i>Translational Oncology</i> , 2021 , 15, 101263	4.9	1
206	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
205	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302	3.2	1
204	Renal Cancer. <i>UNIPA Springer Series</i> , 2021 , 755-774	0.1	0
203	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300	59.2	263
202	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021 , 11, 682449	5.3	3
201	Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	4
200	Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021 , 11, e434	5.7	2
199	Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	4
198	Patient associations and clinical oncology research: how much does a patient's voice really matter?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 433-440	2.2	0
197	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281	6.7	5
196	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211022870	3.2	1
195	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 261-268	3.8	1

194	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320	2.2	0
193	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021 , 19, 328	8.5	0
192	Update on radioligand therapy with Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. <i>Tumori</i> , 2021 , 3008916211037732	1.7	0
191	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). <i>Oncology</i> , 2021 , 99, 747-755	3.6	2
190	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021 , 32, 1511-1519	10.3	24
189	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2021 ,	10.2	10
188	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
187	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 121-125	2.7	5
186	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. <i>Tumori</i> , 2020 , 300891620915786	1.7	0
185	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102057	14.4	13
184	Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. <i>Tumori</i> , 2020 , 106, 406-412	1.7	1
183	Current Understanding of Urachal Adenocarcinoma and Management Strategy. <i>Current Oncology Reports</i> , 2020 , 22, 9	6.3	13
182	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 134-134	2.2	4
181	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 395-405	2.2	216
180	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020 , 126, 4156-4167	6.4	66
179	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501	5	12
178	Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. <i>ImmunoTargets and Therapy</i> , 2020 , 9, 273-288	9	6
177	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725	5.4	3

176	The emerging role of PARP inhibitors in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 715-726	3.5	2
175	Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020 , 136, 195-203	7.5	24
174	Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. <i>Lancet Oncology, The</i> , 2020 , 21, 1538-1539	21.7	4
173	Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal CELL Carcinoma (PIPELINE Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 621-627	2.7	0
172	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1644	5.3	17
171	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
170	Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. <i>Prostate</i> , 2019 , 79, 1683-1694	4.2	10
169	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10
168	Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101891	14.4	10
167	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019 , 2, 699-707	6.7	19
166	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e526-e533	3.3	3
165	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 291-298	3.3	18
164	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 603-611	3.5	7
163	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
162	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846	12.9	90
161	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
160	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
159	Should we use combination therapy for all advanced renal cell carcinoma?. <i>Lancet Oncology, The</i> , 2019 , 20, 1331-1332	21.7	3

158	Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1107-1110	5.4	4
157	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. <i>Future Oncology</i> , 2019 , 15, 2657-2666 ¹	3.6	7
156	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019 , 105, 3-12	1.7	7
155	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
154	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45	2.7	12
153	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e735-e742	3.3	10
152	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 281-283	21.7	4
151	Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. <i>PLoS ONE</i> , 2018 , 13, e0199642	3.7	19
150	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. <i>Tumori</i> , 2018 , 104, 388-393	1.7	1
149	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
148	Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e521-e523	3.3	13
147	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4502-4502	2.2	6
146	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. <i>Global & Regional Health Technology Assessment</i> , 2018 , 2018, 228424031879073	0.2	7
145	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699	3.6	2
144	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018 , 14, 1347-1354	3.6	7
143	Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017 , 61, 250-251	1.7	
142	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 962-971 ^{0.2}	10.2	136
141	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 183-188	5.4	17

140	Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 43-51	7	26
139	Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1395-1402	3.8	19
138	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017 , 92, 269-275	3.6	3
137	Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. <i>Annals of Oncology</i> , 2017 , 28, 2464-2471	10.3	27
136	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017 , 17, 461-467	3.4	4
135	Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy. <i>Tumori</i> , 2017 , 103, 15-21	1.7	8
134	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. <i>Journal of Clinical Investigation</i> , 2017 , 127, 153-168	15.9	37
133	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716	3.3	20
132	Multidisciplinary Approach of Prostate Cancer Patients 2017 , 281-293		
131	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 323-30	5.4	10
130	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4594-4602	5.6	23
129	Improved quality of life is the way to longer life. <i>Lancet Oncology, The</i> , 2016 , 17, 862-863	21.7	5
128	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
127	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 323-34	3.5	5
126	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016 , 34, 236-42	4.3	20
125	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 48-55	3.3	14
124	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5082-5082	2.2	19
123	Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 197-197	2.2	12

122	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 498-498	2.2	15
121	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
120	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
119	Urachal carcinoma: towards a precision medicine. <i>Translational Cancer Research</i> , 2016 , 5, S1307-S1310	0.3	3
118	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2167-72	4.4	15
117	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016 , 11, e0151662	3.7	39
116	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 319-326	3.2	20
115	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 105, 52-64	7	16
114	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
113	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
112	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13	10.3	66
111	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6
110	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 332.e19-24	2.8	12
109	Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. <i>Oncology</i> , 2015 , 88, 133-8	3.6	4
108	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 385-391.e1	3.3	4
107	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
106	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1803-13	59.2	3725
105	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 152-61	3.2	17

104	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 2881-91	3.6	10
103	Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 137-41	3.3	16
102	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
101	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10	7.5	41
100	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015 , 115, 764-71	5.6	16
99	Predicting Molecular Models: Where Are We Going?. <i>EBioMedicine</i> , 2015 , 2, 1594-5	8.8	
98	TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Tumori</i> , 2015 , 101, 701-3	1.7	1
97	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 479-82 ²⁻⁷		25
96	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015 , 9, 263-7	1.2	6
95	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 59-68	3.2	2
94	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
93	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
92	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427	3.7	8
91	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70	3	36
90	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 929-38	3.8	50
89	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014 , 11, 237-49	4.2	8
88	Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?. <i>Cancer Biology and Therapy</i> , 2014 , 15, 486-8	4.6	2
87	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014 , 10, 1611-7	3.6	8

86	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5	1.2	7
85	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 107-16	2.1	5
84	Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 497-510	4.1	8
83	First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. <i>Cancer Biology and Therapy</i> , 2014 , 15, 19-21	4.6	5
82	Response to targeted therapy in urachal adenocarcinoma. <i>Rare Tumors</i> , 2014 , 6, 5529	1.1	12
81	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
80	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014 , 10, 1741-50	3.6	11
79	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014 , 10, 1361-72	3.6	6
78	Butterfly and renal cell cancer: out of chaos comes order. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3083	2.2	2
77	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. <i>Tumori</i> , 2014 , 100, e2-e3	1.7	6
76	Everolimus in advanced solid tumors: when to start, early or late?. <i>Tumori</i> , 2014 , 100, e2-3	1.7	3
75	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014 , 100, e282-e285	1.7	
74	Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014 , 34, 1027-30	2.3	17
73	Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. <i>Anticancer Research</i> , 2014 , 34, 2395-8	2.3	3
72	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
71	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 323-7	6.2	9
70	Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 484-8	3.3	34
69	Complete responses in advanced renal cell carcinoma: utopia or real chance?. <i>Clinical and Experimental Nephrology</i> , 2013 , 17, 151-2	2.5	1

68	Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. <i>European Urology</i> , 2013 , 64, 30-6	10.2	64
67	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013 , 9, 831-43	3.6	5
66	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013 , 9, 1599-607	3.6	6
65	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013 , 24, 2967-71	10.3	21
64	Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. <i>British Journal of Cancer</i> , 2013 , 108, 311-8	8.7	43
63	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026	3.7	52
62	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012 , 62, e5-6; author reply e7-8	10.2	1
61	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37
60	The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. <i>BJU International</i> , 2012 , 110, 998-1003	5.6	35
59	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1571-7	3.5	31
58	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. <i>Tumori</i> , 2012 , 98, 394-394	1.7	4
57	New Perspectives in Advanced Genitourinary Malignancies. <i>Tumori</i> , 2012 , 98, 267-269	1.7	1
56	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012 , 16, 464-7	2.5	25
55	Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 130-3	3.3	3
54	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1089-96	3.5	5
53	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 303-13	3.2	14
52	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1001-8	4.6	5
51	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012 , 107, 1227-32	8.7	18

50	Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 107-11	3.2	2
49	Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012 , 23, 247-54	2.4	4
48	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012 , 98, 267-9	1.7	1
47	Management of advanced genitourinary tumors. <i>Tumori</i> , 2012 , 98, 264-6	1.7	
46	Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. <i>Tumori</i> , 2011 , 97, 115-118	1.7	1
45	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011 , 108, 223-7	5.6	6
44	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011 , 108, E250-7	5.6	67
43	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. <i>British Journal of Cancer</i> , 2011 , 104, 1256-61	8.7	60
42	Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. <i>Neurological Sciences</i> , 2011 , 32 Suppl 2, S217-9	3.5	1
41	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1631-40	3.5	16
40	Role of sorafenib in renal cell carcinoma: focus on elderly patients. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1689-92	3.5	8
39	Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. <i>Annals of Oncology</i> , 2011 , 22, 1812-23	10.3	109
38	Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. <i>Oncology Research</i> , 2011 , 19, 403-6	4.8	3
37	Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. <i>British Journal of Cancer</i> , 2010 , 102, 80-6	8.7	52
36	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010 , 96, 794-795	1.7	1
35	Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010 , 7, doi:10.1038/nrurol.2010.2-c1; author reply doi:10.	5.5	1
34	Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. <i>Medical Oncology</i> , 2010 , 27, 1267-8	3.7	1
33	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. <i>Tumori</i> , 2009 , 95, 501-507	1.7	3

32	Activity of sunitinib in patients with advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 319-20; author reply 320	2.2	7
31	Neuroendocrine tumors (NETs). <i>Clinical Therapeutics</i> , 2009 , 31, 2060-1	3.5	1
30	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009 , 3, 79-87	4.3	3
29	252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC). <i>European Urology Supplements</i> , 2009 , 8, 183	0.9	15
28	Merkel Cell Carcinoma after Liver Transplantation: A Case Report. <i>Tumori</i> , 2007 , 93, 323-326	1.7	7
27	Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome. <i>Tumori</i> , 2007 , 93, 201-203	1.7	4
26	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 637-42	3.5	178
25	Pulmonary carcinoid tumours: indolent but not benign. <i>Oncology</i> , 2007 , 73, 162-8	3.6	23
24	Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. <i>Oncology</i> , 2007 , 73, 204-9	3.6	27
23	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. <i>Cancer</i> , 2006 , 107, 2474-81	6.4	59
22	Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. <i>Tumori</i> , 2006 , 92, 72-75	1.7	12
21	Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors. <i>Tumori</i> , 2006 , 92, 531-535	1.7	12
20	Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. <i>Tumori</i> , 2006 , 92, 531-5	1.7	6
19	In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 309-10	4	13
18	Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2155-61	2.2	178
17	Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. <i>Annals of Oncology</i> , 2005 , 16, 1374-80	10.3	57
16	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. <i>Tumori</i> , 2004 , 90, 535-546	1.7	29
15	Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors. <i>International Journal of Biological Markers</i> , 2004 , 19, 295-304	2.8	15

14	Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. <i>International Journal of Biological Markers</i> , 2004 , 19, 295-304	2.8	12
13	Update on the treatment of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 631-425	3.5	18
12	Current Treatments of Neuroendocrine Tumors Role of Biotherapy and Chemotherapy. <i>Tumori</i> , 2003 , 89, 111-116	1.7	4
11	Renal Cancer Treatment: A Review of the Literature. <i>Tumori</i> , 2003 , 89, 476-484	1.7	13
10	Levofloxacin: update and perspectives on one of the original respiratory quinolones. <i>Expert Review of Anti-Infective Therapy</i> , 2003 , 1, 371-87	5.5	12
9	A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. <i>Cancer</i> , 2002 , 94, 299-304	6.4	23
8	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. <i>Annals of Oncology</i> , 2002 , 13, 614-21	10.3	85
7	Advances in diagnosis and therapy of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 371-81	3.5	4
6	Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer. <i>Tumori</i> , 2001 , 87, 364-371	1.7	6
5	Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial. <i>Cancer</i> , 2000 , 89, 763-8	6.4	27
4	Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. <i>Tumori</i> , 1999 , 85, 6-11	1.7	4
3	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. <i>Cancer</i> , 1999 , 86, 858-65	6.4	210
2	5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. <i>Cancer</i> , 1998 , 83, 372-8	6.4	121
1	Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity		1